Tags

Type your tag names separated by a space and hit enter

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
AIDS Res Hum Retroviruses. 2020 05; 36(5):357-366.AR

Abstract

Intramuscular depo-medroxyprogesterone acetate (DMPA-IM) is the most widely used hormonal contraceptive in sub-Saharan Africa. Previous meta-analyses of observational studies found a significant 40%-50% increased risk associated with DMPA-IM use, relative to no contraception or infrequent condom use. This raised substantial concerns, although these studies had important limitations. Consequently, the open-label randomized Evidence for Contraceptive Options and HIV Outcomes trial was conducted, designed primarily to detect a 50% or greater difference in HIV risk between DMPA-IM, the levonorgestrel (LNG) implant, and the copper-intrauterine device. The ECHO study, published in July 2019, concluded that there is no substantial difference in HIV risk among the methods evaluated, and that all three methods are safe and highly effective. In response, the WHO relaxed the Medical Eligibility Criteria for DMPA-IM use among women at high HIV risk in August 2019. However, two of the three comparisons in the ECHO trial could rule out neither a 50% increase nor no change in HIV risk for one contraceptive compared with another. The study had limitations and the results contained considerable uncertainty. They also did not inform on associated HIV risk for any one of the individual methods due to the absence of a control group such as no contraception or only infrequent condom use. The HIV risks associated with LNG implant and copper-IUD relative to no contraception or infrequent condom use are unknown and these cannot be seen as controls, nor did the authors claim them to be. The results will be discussed in the context of their limitations, what they add to the body of work to date on contraception and HIV acquisition, and the implications of the findings and reports thereof for future research and contraceptive choice.

Authors+Show Affiliations

Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

31797677

Citation

Hapgood, Janet P.. "Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated With an Increased Risk for HIV Acquisition? the Jury Is Still Out." AIDS Research and Human Retroviruses, vol. 36, no. 5, 2020, pp. 357-366.
Hapgood JP. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out. AIDS Res Hum Retroviruses. 2020;36(5):357-366.
Hapgood, J. P. (2020). Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out. AIDS Research and Human Retroviruses, 36(5), 357-366. https://doi.org/10.1089/AID.2019.0228
Hapgood JP. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated With an Increased Risk for HIV Acquisition? the Jury Is Still Out. AIDS Res Hum Retroviruses. 2020;36(5):357-366. PubMed PMID: 31797677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out. A1 - Hapgood,Janet P, Y1 - 2020/01/22/ PY - 2019/12/5/pubmed PY - 2019/12/5/medline PY - 2019/12/5/entrez KW - DMPA KW - Depo-Provera KW - ECHO trial KW - HIV KW - contraception SP - 357 EP - 366 JF - AIDS research and human retroviruses JO - AIDS Res Hum Retroviruses VL - 36 IS - 5 N2 - Intramuscular depo-medroxyprogesterone acetate (DMPA-IM) is the most widely used hormonal contraceptive in sub-Saharan Africa. Previous meta-analyses of observational studies found a significant 40%-50% increased risk associated with DMPA-IM use, relative to no contraception or infrequent condom use. This raised substantial concerns, although these studies had important limitations. Consequently, the open-label randomized Evidence for Contraceptive Options and HIV Outcomes trial was conducted, designed primarily to detect a 50% or greater difference in HIV risk between DMPA-IM, the levonorgestrel (LNG) implant, and the copper-intrauterine device. The ECHO study, published in July 2019, concluded that there is no substantial difference in HIV risk among the methods evaluated, and that all three methods are safe and highly effective. In response, the WHO relaxed the Medical Eligibility Criteria for DMPA-IM use among women at high HIV risk in August 2019. However, two of the three comparisons in the ECHO trial could rule out neither a 50% increase nor no change in HIV risk for one contraceptive compared with another. The study had limitations and the results contained considerable uncertainty. They also did not inform on associated HIV risk for any one of the individual methods due to the absence of a control group such as no contraception or only infrequent condom use. The HIV risks associated with LNG implant and copper-IUD relative to no contraception or infrequent condom use are unknown and these cannot be seen as controls, nor did the authors claim them to be. The results will be discussed in the context of their limitations, what they add to the body of work to date on contraception and HIV acquisition, and the implications of the findings and reports thereof for future research and contraceptive choice. SN - 1931-8405 UR - https://www.unboundmedicine.com/medline/citation/31797677/Is_the_Injectable_Contraceptive_Depo_Medroxyprogesterone_Acetate__DMPA_IM__Associated_with_an_Increased_Risk_for_HIV_Acquisition_The_Jury_Is_Still_Out_ L2 - https://www.liebertpub.com/doi/10.1089/AID.2019.0228?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -